GenEdit

Gen Edit

Biotechnology, 681 Gtwy BLVD, South San Francisco, California, 94080, United States, 11-50 Employees

genedit.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 51********

Who is GENEDIT

GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positiv...

Read More

map
  • 681 Gtwy BLVD, South San Francisco, California, 94080, United States Headquarters: 681 Gtwy BLVD, South San Francisco, California, 94080, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies
  • Kunwoo Lee CEO:   Kunwoo Lee

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from GENEDIT

GenEdit Org Chart and Mapping

Kunwoo Lee

Chief Executive Officer & Co-Founder

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding GenEdit

Answer: GenEdit's headquarters are located at 681 Gtwy BLVD, South San Francisco, California, 94080, United States

Answer: GenEdit's phone number is 51********

Answer: GenEdit's official website is https://genedit.com

Answer: GenEdit's revenue is $10 Million to $25 Million

Answer: GenEdit's SIC: 2834

Answer: GenEdit has 11-50 employees

Answer: GenEdit is in Biotechnology

Answer: GenEdit contact info: Phone number: 51******** Website: https://genedit.com

Answer: GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access